In a move that may not surprise anyone (given the continuing consolidation of advisors inside the JP Morgan ecosystem), we are hearing that JP Morgan Securities is about to bow…
Moderna (MRNA) has surged over 300% since the start of the year. Analysts at JP Morgan, concerned about the company’s valuation, have downgraded the stock to neutral.
Other industry experts agree.…